Member Info for sadoldgit

Phase1a trial is complete we just await the data.

We have competitors for sure.

Ropsacitinib ought to do well being a Tkk2 Jak2 inhibitor should they have over come issues with EPO causes by Jak2. Jak 2 will Pair with Jak2 to create this. Basically over production of red blood cells that likely to lead to blood clots.

However, from small snippets l have seen this does not appear to create a significant problem.

Dear old Deucravacitinib which has a safety profile without a black box warning looks to be bettered by both SDC1801 and Ropsacitinib.

With regards to IBD, take into account that we have also 1802 which is now undergoing patent protections for use in immunotherapy.

It has been very quiet on the 1802 front due to several setbacks the company has experienced and can now be put behind us.

UC and CD are very similar. Not much difference between.

I have a friend l have known for years, diagnosed with UC and CD, it is problematic to him.

Jak 1 and 3 inhibitors pair nicely and early generation inhibitors have given good efficacy albeit encountering problems with adverse events.

No problem with Deucravacitinib here. It don't have any black box warnings, but at the same time is about as much use as a handbrake on a canoe.

GSK state it regulates the active site

No it don't. It is an allostetic Tyk2 inhibitor which signals via the JH2 domain which is also known as the regulatory domain.

Not quite the same is it.

The term Regulating can mislead here.

How does Tyk2 regulate Jak3?

Which STAT pathways does it use?

It does not.

The only Jaki that will Pair with Jak3 is Jak1.

Indeed also you will need a pre determined degree of selectivity here.

You will also now have a problem with Jak2 as you cannot have 100% selectivity of any of the Jsks 1, 3 and 3.

Further more you will need molecules to formulate the compounds.

Good idea that Sareum have their 31 molecules protected by patent. Nobody else can use them

Anyone remember BMS claiming the novel use of Deuterium in its molecules. Big song and dance made.

It exists in Sareum molecules, not all l might add.

I would suggest Tim looking at raising finance whilst at the Bio meeting.

I don't 5hink write will get much forth coming this week on any front.

I am of the firm opinion that Dareum will be looking at releasing news of attainment of non dilution finance along with safety results with intent to start phase 2a trial.

Regards

Genedrive were over 2 pounds a share early 2020.

Scandalous and corrupt.

Commercialisation can only happen after approval by the regulatory for use as a therapy in a given indication.

Sareum would have no control over this.

However they do to an extent have control over on licence.

As a compound reaches higher stages of development so does its value increase.

Typically phase 2 compound has far more value than phase1 compound.

Most important aspect is safety.

It can now go to next stage.

Phase 2 is basically proof of concept and is the compound likely to provide sufficient efficacy

With satisfactory safety profile.

Most preclinical data will give an indication as to efficacy and the ability to treat a disease.

We have MTD which basically means a threshold point where we begin to see a likelihood of a fatality.

This is not quite the same as serious adverse events.

Serious adverse events tend to become identified much later down the line in late phase2 /phase3 trials.

Deucravacitinib with its portrayed excellent safety profile does have warnings of side effects.

Essentially what we are looking at is having a similar safety profile as Deucravacitinib with the added advantage if increased efficacy from the Jakis.

TM said this 3 years ago along with the firm belief that their compound will prove to be superior to that of Deucravacitinib.

Preclinical indicated potential greater efficacy over as has also TM.

Unfortunately the 2 intellectual giants of the 21st century over on ADVN think otherwise. Even to the point of ignoring or refusal to read research papers which support claims of 1801.

A value will be attributed to 1801. The difficulty is in what indications other than psoriasis can be identified prior to commercialisation.

As far as l see it, whatever the next stage whether phase1b or phase 2a it will on a short period of time be onlicenced.

Joint ventures, partnering, investors will be at the June meeting.

1802 l feel needs to be tad further down the development line.

All in all a payment up front and backend milestones of up to a billion dollars is achievable on 1801 alone.

SD

Before Riverfort came aboard we were a 70 million market cap company. We have successfully completed phase1a trial and await confirmation thereof.

Should prove no problem bettering Deucravacitinib in Psoriasis.

Steady Danny/critical thinker had posted over at ADVFN of the achievement of

At 47p per share and 107.9 million shares we are now a 50 million pound market cap company.

No problem blueandwhite. I should not really respond to the negatives but l do find them.a tad annoying.

I will ignore them

Regards.

Blueandwhite l will post when l like to who l like and how l like.

Regards

Joan Baez if l remember correctly.

May get some sellers later. Nothing wrong in that

.

Will be some BS from Beavis and Butthead over on ADVN.

They assume that l post under a different handle over there.

Never have done never will.

So not only do we have the two mongs don't make a right.

But also the two mongs can't get anything right.

Sum ting wong wid de mong.

I wonder if they dare short at the moment. One has claims to work in finance.

Both been burned by their own inadequacy, ignorance and stupidity.

Good week coming here l feel.

Regards

Pembrolizumab is a monoclonal anti body.

It has been around several years.

It is a PD-1 inhibitor as opposed to a checkpoint kinase inhibitor.

PD-1 inhibitors tend to work on identifying and destruction of a cell from the external. Checkpoint kinase 1 inhibitors work from cell internals.

However, in saying this Sierro Oncology in their final stage trial design had 737 in combo with Pd-1 inhibitor and also Wee1 inhibitor.

Pancreatic cancer and high grade serious varian cancer still is an area of urgent unmet need.

There is no escaping the DNA damage repair pathway.

Vital important that compatible and not serious adverse event in combo therapies become recognised.

Regards

Https://www.biocat.cat/en/current-news/agenda/bio-international-convention-san-diego-2024

Long read. June 24

https://www.sciencedirect.com/science/article/pii/S2590098624000101

Nothing 2 months ago to indicate news on safety data imminent.

Regards

There will exist a reason for no disclosure of the current owner of on licence.

The importance of the Chk1 inhibitor is known as well as the downsides, primarily to establish maximum efficacy it needs to be used in combo.

There are many partners that are suitable, some more so than others.

737 is not the only CHK1 inhibitor being investigated in combination therapy.

It is a very competitive industry.

Sareum have always been water tight.

Without knowing the company that has taken 737 on there is very little to go on.

Competitors will have no idea either.

No pipeline, no clinical stage preparation info, no nothing.

There are people that will know, l doubt they will be as water tight as Sareum.

How much do the CPF know?

In original licence agreement feedback was l believe required on a quarterly basis.

After 12 months of no progression or supportive information as to intent, then return of licence with all IP material.

5 months and info received zilch.

737 gave excellent preclinical results in some cancers including, small cell lung cancer, colorectal and prostrate with different inhibitors.

In addition early preclinical good results in head and neck cancers albeit with 245744 or 244745 not remember 100% but molecule tweak produced 244737 with either the addition of or removal of a cyclic ring. Long time ago!

My opinion for what it is worth is developments are afoot on 1801.

1802 is still early stage and to give that value Indication identification needs to be disclosed along with confirmation of drug candidate to be entered into trial.

Regards

About time it nudged up!

Very nice too Mafuta,

PH I believe were bought on board as access finance as they are investment bankers.

Almost spelled it right, b key miles away from w key.

Sareum are not the client as we know. The purpose of the investment banker is to obtain property in one form or another at the cheapest possible price for their client which is the investor.

RF done exceedingly well out of this at the cost to Sareum of dilution to the company of around 40%.

I dare say they would have bust the company, take the company over and sell on as a viable concern.

With a current market Cap of around 44 million as a shareholder l am pleased they did not succeed.

We await data result and interpretation thereof.

A week at most l would think às will go from person to person awaiting signatures.

Do we get an announcement at some time of on licence for 1801 or Co partner providing some of finance.

Psoriasis should be nigh a dead cert.

Other auto immune have very little idea.

Biomarker data should give an indication of which we await news of in full report.

Sareum.will have this data already.

Very likely the interested parties too.

News with regards to 1801 we await on more than one front.

On past performance of PH fiasco, would you seriously want any further involvement?

100% certain that PH bought RF on board.

Within a week of PH coming on board SAR SP dropped over 50% in one day?

They are there to provide a service and the service we have had has been less than satisfactory.

Regards

Clearly Sareum do not have the intention of using PH in any licensing deal. I wonder why?

Good news indeed elcap.